Associate Professor
University of Texas MD Anderson Cancer Center
Houston, TX
Yinghong Wang, MD, MSc, PhD, has a strong academic background and profound clinical experience from world renowned medical programs (Johns Hopkins, Cleveland Clinic). She has broad research collaboration network worldwide and holds more than 100 peer-reviewed publications and numerous international conference presentations in her academic career. Her specialized areas include Inflammatory Bowel Disease (IBD), fecal microbiota transplantation (FMT), and cancer immunotherapy induced gastrointestinal toxicities. At MD Anderson, Dr. Wang has been recognized for her expertise in managing cancer immunotherapy induced GI toxicities and her initiative in setting up IBD clinic and FMT service. She is taking a leading role on the management of immunotherapy related toxicities and serves as the chair of institutional immunotherapy toxicity working group. Over the past 3 years, she has served as guideline panel member for immunotherapy induced colitis in four national and international oncology societies and gastroenterology society (ASCO, SITC, NCCN, ESMO, AGA). Dr. Wang also published a new book entitled “Managing Immunotherapy Related Organ Toxicities, A Practical Guide” as the editor in 2022. Dr. Wang and her team achieved a breakthrough of successful treatment for immunotherapy induced colitis refractory to immunosuppressant by FMT as a compassionate treatment. This pioneering work was published on Nature Medicine with great impact in this field. Over the past 5 years at MD Anderson, Dr. Wang and her collaborators from more than 15 other academic centers worldwide published numerous scientific articles in the oncology field in many prestigious journals. Dr. Wang and her team have launched three clinical trials in treating colitis and demonstrated promising result.
Immune Checkpoint Inhibitor Complications
Friday, October 20, 2023
4:00 PM – 4:20 PM PT